<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293994</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11222010-7229</org_study_id>
    <secondary_id>IRB #16198</secondary_id>
    <nct_id>NCT01293994</nct_id>
  </id_info>
  <brief_title>A Study of Genetic Variation Influencing Pain and Response to Opioid Medications</brief_title>
  <official_title>A Study of Genetic Variation Influencing Pain and Response to Opioid Medications in Patients With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be collecting saliva DNA samples from chronic back pain patients. The&#xD;
      investigators hope to find candidate genes associated with response to opioid medication by&#xD;
      correlating molecular genetics data with pain measurement and opioid responsiveness data&#xD;
      including opioid hyperalgesia and opioid analgesic tolerance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hope to find a genetic association with various physiologic responses to&#xD;
      opioid medication in patients who suffer from chronic pain (e.g. OIH vs. analgesic tolerance,&#xD;
      baseline pain sensitivity, etc.). This has never been done before, and if it proves&#xD;
      successful, it could provide physicians a greater understanding of why some chronic opioid&#xD;
      users continue needing increased doses of opioids. This data may also help predict which&#xD;
      patients will do well with chronic opioid therapy and which ones may not. Initial data with&#xD;
      OPRM1 gene analysis in humans already implicates certain SNPs with opioid responsiveness and&#xD;
      there have been suggestions for screening patients for OPRM1 prior to initiating opioid&#xD;
      therapy in order to optimize their treatment response (Reynolds et al., 2008).&#xD;
&#xD;
      Clin Lab Med. 2008 Dec;28(4):581-98. The value of CYP2D6 and OPRM1 pharmacogenetic testing&#xD;
      for opioid therapy. Reynolds KK, Ramey-Hartung B, Jortani SA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Do not have necessary resources to continue&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic association with various physiologic responses to opioid medication in patients</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva biospecimen collection will be performed via mail or in person. The PI will send&#xD;
      participants a letter informing them of the opportunity to participate in a study of genetic&#xD;
      variation influencing pain and opioid responsiveness phenotypes. If participants agree to&#xD;
      provide a saliva biospecimen and to participate in the study, an informed consent letter and&#xD;
      an Oragene™ DNA Self-Collection Kit, in disk format OG-250 (DNA Genotek, Inc., Ottawa,&#xD;
      Ontario, Canada) will be sent to the participant by the PI. According to the manufacturer&#xD;
      instructions, participants will provide a 2 ml saliva sample, which will be preserved using&#xD;
      the reagents provided within the Oragene™ kit. Saliva samples are considered stable at room&#xD;
      temperature for 5 years by Oragene™.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any gender, ages 18-70, of any ethnic background&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patient, aged 18-71&#xD;
&#xD;
          2. Recipient of chronic opioid therapy&#xD;
&#xD;
          3. Patient is able to produce a saliva sample&#xD;
&#xD;
          4. If a past study participant, patient will have agreed to be contacted for future&#xD;
             studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        a. not meeting inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Larry Fu-nien Chu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Larry Fu-nien Chu</investigator_full_name>
    <investigator_title>Professor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>Chronic Pain, Genetic Variation, Opioid Medications, Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

